Biofidelity appoints Wendy J. Levin MD MS as Chief Medical Officer
Experienced US-based medical oncologist joins Biofidelity prior to launch of first diagnostic product
US-trained oncologist & hematologist with over 15 years industry experience in translational medicine and drug development
Global clinical lead for the Pfizer SMO Inhibitor, Daurismo, from pre-IND to FDA approval
Clinical development and medical affairs leadership for multiple publicly-traded and private companies
Biofidelity Ltd, the cancer diagnostics company, today announces the appointment of Wendy J. Levin MD MS as Chief Medical Officer, based in the US. Following Biofidelity’s recent Series A financing, supported by experienced investors BlueYard Capital, Longwall Ventures and Agilent Technologies, the Company is now focused on expanding its executive team as it works towards launch of the Identi-Lung panel in 2021. Dr. Levin’s appointment follows those of former Roche executive Heiner Dreismann as Chairman, Stephen Miller as Chief Commercial Officer and Robert Osborne as Chief Operating Officer.
Dr. Levin joins Biofidelity with over 15 years of experience in the biotechnology industry, spanning a broad range of disease indications, therapeutic targets and early- to late-phase development. Dr. Levin began her undergraduate and graduate career at the University of California Los Angeles (UCLA), where, under the guidance of Dr. Dennis J. Slamon, she co-authored the first publications on HER-2/neu in breast and ovarian cancers. She completed her Internal Medicine residency at University of Southern California, and her Fellowship at the University of Washington/Fred Hutchinson Cancer Research Center. As an Attending Physician at the University of Washington, she focused on malignant hematology and sarcoma, while maintaining an active laboratory presence.
Dr. Levin joined Pfizer in her first industry role, where she led the translational and clinical development of Daurismo from IND to the design and execution of the FDA Registration trial in elderly unfit acute myeloid leukemia (AML). She subsequently served as Vice President and acting Chief Medical Officer of two publicly-traded companies, where she led clinical development and medical affairs, supported business development, and led analyst interactions and presentations for venture capital fundraising efforts.
Since then, Dr. Levin has provided strategic and tactical support for pre-IPO start-ups, publicly-traded Fortune 500 companies and venture capital firms. In these senior level leadership roles, she has led health authority and regulatory interactions, executed clinical advisory boards, provided clinical leadership for first-in-human studies to Phase 3 registration trials, and supported clinical, translational and biomarker efforts for large and small molecules, ADCs, stem cell transplantation, cell therapies and immuno-oncology assets.
Biofidelity is building a truly world-class team as we focus on harnessing the power of our unique technology for the benefit of cancer patients and clinical researchers. Wendy’s expertise in the design and execution of global clinical trials will be invaluable in achieving regulatory approval for Biofidelity’s assays and driving broad adoption of our flagship product, Identi-Lung. Her wealth of experience with major pharmaceutical and biotech companies will also support the use of our technology in companion diagnostic research. With the addition of Wendy to our fast-growing leadership team, Biofidelity is moving closer to revolutionizing the availability of precision cancer diagnostics, enabling oncologists to provide all patients with the right treatment at the right time.
Dr. Barnaby Balmforth
Chief Executive Officer of Biofidelity
What attracts me to Biofidelity is the tremendous opportunity to help patients receive the right drug for their diagnosis in a timely and cost-effective manner. As an oncologist, I have seen first-hand the need for molecular diagnosis to guide actionable therapeutic decision making. The costs and slow turnaround time of DNA sequencing to obtain this information results in delays in treatment of large numbers of patients. I am excited by the opportunity to lead the clinical strategy and development at Biofidelity, to ensure that far greater numbers of patients have access to the precision testing they need.